UPDATE 2-Osiris stops enrollment in Crohn's disease trial
* Stops enrollment in late-stage trial of lead drug candidate
* Cites flaw in trial design
* Says one dose arm was unlikely to meet main trial goal
* Shares drop 31 percent (Adds analysts' comments, updates stock movement)
By Esha Dey
BANGALORE, March 27 (Reuters) - Stem cell research firm Osiris Therapeutics Inc (OSIR.O: Quotazione) said it stopped enrolling patients in a late-stage trial to test its lead drug candidate, Prochymal, in Crohn's disease due to design flaws in the study.
The company would continue the trial with patients already enrolled and use data from the trial to redesign future studies. However, it does not expect to get Prochymal approved for Crohn's disease through this trial.
Leerink Swann analyst William Tanner, who had expected the trial to end without difficulties, said he expects the Crohn's disease trial to get pushed by a couple of years.
Tanner does not expect the enrollment halt and design flaws to impact other indications in which the drug is being tested. Continua...